Bank Of New York Mellon Corp Chinook Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$21.53 - $26.8 $4.21 Million - $5.24 Million	195,352 New	195,352 $4.52 Billion
Q4 2022 Feb 14, 2023	BUY	$18.63 - $27.35 $4.12 Million - $6.05 Million	221,059 New	221,059 $5.79 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $310,102 - $413,882	17,710 Added 9.19%	210,492 $4.14 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $496,952 - $742,073	39,472 Added 25.75%	192,782 $3.37 Million
Q1 2022 May 11, 2022	BUY	$12.02 - $16.69 $141,343 - $196,257	11,759 Added 8.31%	153,310 $2.51 Million
Q4 2021 Feb 11, 2022	BUY	$10.69 - $16.83 $127,766 - $201,152	11,952 Added 9.22%	141,551 $2.31 Million
Q3 2021 Nov 12, 2021	BUY	$11.5 - $14.86 $141,220 - $182,480	12,280 Added 10.47%	129,599 $1.65 Million
Q2 2021 Aug 11, 2021	BUY	$13.6 - $18.98 $642,450 - $896,596	47,239 Added 67.41%	117,319 $1.66 Million
Q1 2021 May 13, 2021	SELL	$14.17 - $19.11 $47,441 - $63,980	-3,348 Reduced 4.56%	70,080 $1.09 Million
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $873,793 - $1.54 Million	73,428 New	73,428 $1.16 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.